Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Appointment of Executive Director

2nd Oct 2018 07:00

RNS Number : 5960C
Cello Health PLC
02 October 2018
 

2 October 2018

Cello Health plc

("Cello", the "Company", or the "Group")

Appointment of Executive Director

Further to the announcement of the Interim Results on 19 September 2018, Cello Health plc (AIM: CLL), the global healthcare-focused advisory Group, is pleased to announce that Julia Ralston has been appointed Executive Director of the Company with immediate effect, bringing the executive team to a total of four. Julia's presence on the Board will ensure appropriate levels of governance and control around Cello's expanding US business.

Julia is CEO of Cello Health in the US, having joined the Group as CEO of MedErgy in 2011 following its acquisition by Cello. Julia is responsible for Cello's strategic growth in the US and facilitating collaboration in the region across the Group's capabilities in consulting, insight, and communications.

 

Enquiries:

Cello Health plc

020 7812 8460

Mark Scott, Chief Executive

Mark Bentley, Group Finance Director

Cenkos Securities plc

020 7397 8900

Mark Connelly

Harry Hargreaves

Buchanan

020 7466 5000

Mark Court

Jamie Hooper

Sophie Wills

 

About Cello Health plc

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com

 

 

Regulatory information

Full name (age)

Current directorships:

Previous directorships / partnerships (over the last five years):

Julia Anne Ralston (61)

Cello Health Inc.

Cello Health BioConsulting Inc.

Cello Health Consulting Inc.

Defined Health Inc.

Worldwide Promedica Inc.

Insight Research Group US Inc

Cello Health Advantage Inc

MedErgy HealthGroup Inc

Cello Health Communications Inc

MedErgy Scientific Inc

SciFluent Communications Inc

MedErgy Communications Inc

None

 

As at today's date, Ms. Ralston holds 580,405 ordinary shares of 10p each in the capital of the Company.

There are no further disclosures to be made pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of the appointment of Ms. Ralston.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOAEASEFESEPFFF

Related Shares:

CLL.L
FTSE 100 Latest
Value8,809.74
Change53.53